HDAC9 and acute myeloid leukemia: However, clinical results have shown that HDAC inhibitors are not effective as a monotherapy for AML, and in vitro experiments have shown that HDAC inhibitors and DNMT inhibitors cooperate to induce the re-expression of silent genes in LSCs (53).